Indiana’s top state budget official finds new job
The top state budget official under Indiana Gov. Mitch Daniels has decided to move into an executive position with Indiana University Health when the governor's term ends in January.
The top state budget official under Indiana Gov. Mitch Daniels has decided to move into an executive position with Indiana University Health when the governor's term ends in January.
WellPoint Inc.'s third-quarter earnings trumped Wall Street expectations, but the health insurer's stock tumbled Wednesday after President Barack Obama won re-election, a victory that could help cement the future of his health care overhaul.
Many Indiana Republicans want to use the Healthy Indiana Plan to expand Medicaid coverage in Indiana to more low-income adults. But the program—which offers health insurance based on health savings accounts to uninsured adults—has managed to attract just one-third of the Hoosiers it was designed for and has cost about twice as much per enrollee as predicted.
About 100 workers will staff the new plant, which will be constructed by spring 2014 and ready for operations in 2015. But only “some” of that number will be new hires.
The Indianapolis-based drugmaker plans to expand its local insulin plants to make insulin cartridges to meet what it describes as growing demand in the United States.
The European Union has approved Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged prostate.
Indianapolis Colts rookie quarterback Andrew Luck on Tuesday will announce his first local sponsorship deal, a four-year pact with Riley Hospital for Children at Indiana University Health.
The Warsaw-based maker of orthopedic implants beat analysts’ estimates with its third-quarter earnings, but lowered its full-year forecast.
Shareholders of Amerigroup Corp. overwhelming approved the Virginia company’s sale for $4.9 billion to Indianapolis-based health insurer WellPoint Inc. in a vote on Tuesday. The vote clears the way for the acquisition to close before the end of the year.
Eli Lilly CEO John Lechleiter on Tuesday called for creation of a “world-class” research institute in Indianapolis to bring together scientists from universities and corporations to develop new medical therapies and companies.
Eli Lilly and Co. said dulaglutide lowered blood sugar better than three existing diabetes drugs in three Phase 3 clinical trials. Analysts expect the drug to hit the market in 2014 or 2015 and become a blockbuster.
Researchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts to find a cure have been unsuccessful.
Separate Medicare and Medicaid divisions each will sell plans for those government-backed insurance programs. Another will handle commercial and individual business, and a specialty unit will provide dental, vision and disability coverage.
Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
Eli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease, according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than 5 percent on the news.
New health insurance coverage created by the 2010 health reform law will attract a lower-income, less-educated and more diverse set of customers than the insurance markets that exist today, according to a new analysis by PricewaterhouseCoopers. And that could create challenges for doctors and hospitals trying to care for those patients.
Three area hospital groups—St. Vincent Health, Community Health Network and Suburban Health Organization—have agreed to join forces to manage patients’ health and strike new kinds of contracts with employers and health insurers.
With volunteer leader Nancy Shepard at the helm, IWIN Foundation has distributed $875,000 in grants to breast cancer patients. Recipients have ranged in age from 18 to 90.
Sam Odle, who retired from Indiana University Health in July as chief operating officer, is joining the local lobbying firm as a senior policy adviser, representing clients in the health care and life sciences sectors.
The departure of Dr. George Sledge likely will sap the breast cancer research program at the Indiana University Melvin and Bren Simon Cancer Center of about $500,000 in annual funding. But the program Sledge built over the past three decades mostly will remain intact.